Polymerase in Medical Technology
Navigation Links
Polymerase in Medical Technology
... (HCV). PSI-7851 is a second generation nucleotide polymerase inhibitor of HCV.
PSI-7851 Phase 1 ... than Pharmasset's first generation nucleoside polymerase inhibitor, RG7128 (formerly known as R7128). In ... which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently ...
... R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing ... an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load ... with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset. Further studies ...
... the Company's investigational non-nucleoside polymerase inhibitor, demonstrated potent antiviral activity ... to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of ... protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These ...
... Results for Non-Nucleoside HCV polymerase Inhibitor Being Presented at AASLD SAN DIEGO, ... ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the ... investigational hepatitis C non- nucleoside polymerase inhibitor. ANA598 Phase I Study Results In ...
... Study of ANA598, a Non-Nucleoside NS5B polymerase Inhibitor, in Healthy Volunteers", will present ... Combinations of Antiviral Agents that Include HCV polymerase Inhibitor ANA598 have the Potential to Overcome ... inhibitor and a representative nucleoside polymerase inhibitor. About ANA598 Preclinical ...
... support the potential for IDX184 to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and tolerability, coupled ... new drug applications in the coming months from our non-nucleoside polymerase inhibitor and protease inhibitor programs, we are closer to achieving our ...
... first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic ... study to further support the efficacy and safety of R7128, and nucleoside polymerase inhibitors as a class," said Michelle Berrey, MD, MPH, Pharmasset's Chief ...
... hepatitis C virus (HCV). PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice ... to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through its collaboration ...
... Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar ... 1 Study of BSI-201, a Small Molecule Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with Advanced Solid Tumors When: Monday, ...
... infectious diseases, today announced preclinical data from the company's polymerase and protease inhibitor programs for the treatment of hepatitis C. These ... being held this week in Milan, Italy. Second-Generation Nucleoside polymerase Inhibitor Program IDX184 is a nucleotide prodrug derived from Idenix's ...
... in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be ... developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist ...
... preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight ... platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BiPar has successfully advanced BSI-201 from an IND to ...
... to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's ... also suggests that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care that is not found with other classes ...
... R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's ... Clinical Development & Chief Medical Officer. "Currently, there are no HCV polymerase inhibitors approved for the treatment of chronic HCV infection. We ...
... licensed by SEQUENOM and known as the AttoSense(TM) HPV assay). Utilizing SEQUENOM's proprietary MassARRAY((R)) system that couples standard polymerase chain reaction (PCR) techniques with mass spectrometry (PCR-MS), study samples were simultaneously screened, genotyped and quantified for each of 13 ...
... infection of which certain types can lead to cervical cancer. Great Basin Scientific's technology has several advantages over the traditional polymerase Chain Reaction (PCR) method that requires the skills of highly-trained technicians and often times multiple rooms to avoid cross contamination of ...
... SNY ) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer ....
... and services, today announced that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction (PCR) test to aid in identifying Influenza A H1N1 Swine-origin (H1N1) flu virus ("S-OIV" or "novel H1N1"), also known as the Swine ....
... the Abbott m 2000 Instrument System The Abbott RealTi m e HIV-1 test runs on the Abbott m 2000, an automated system that uses real-time polymerase chain reaction (PCR) to amplify, detect and measure minute levels of virus in blood samples as well as extremely high levels of these infectious ...
... noted that a Phase 2b triple combination trial of ITMN-191 is planned for initiation in the summer of 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "The Phase 1b ...
... blood pressure, or severity of illness requiring supportive care. Of the 137 patients randomized, 122 age 19 to 101 years had influenza confirmed by polymerase chain reaction (PCR) testing and were included in the intent-to-treat infected (ITTI) patient population; 41 patients received oseltamivir 75 mg ...
... for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, ...
... in 31 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in collaboration with Roche. As previously reported for Cohorts 1 and 2 of this study, R7128 ...
... clevudine in South Korea under the brand name Levovir. "Clevudine's unique mechanism of action as a non-chain terminating nucleoside analog HBV polymerase inhibitor may demonstrate additive antiviral benefit in combination with tenofovir's recently demonstrated antiviral potency in HBV," stated Dr. ...
... R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing ... an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load ... with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset. Further studies ...
... the Company's investigational non-nucleoside polymerase inhibitor, demonstrated potent antiviral activity ... to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of ... protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and ... to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV ... been reported previously for all classes of HCV polymerase inhibitors, including nucleosides. This ...... Results for Non-Nucleoside HCV polymerase Inhibitor Being Presented at AASLD SAN DIEGO, ... ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the ... investigational hepatitis C non- nucleoside polymerase inhibitor. ANA598 Phase I Study Results In ...
... Study of ANA598, a Non-Nucleoside NS5B polymerase Inhibitor, in Healthy Volunteers", will present ... Combinations of Antiviral Agents that Include HCV polymerase Inhibitor ANA598 have the Potential to Overcome ... inhibitor and a representative nucleoside polymerase inhibitor. About ANA598 Preclinical ...
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
... HCV Protease Inhibitor and Non-Nucleoside polymerase Inhibitor Clinical Candidates into ... candidate (IDX375) from its HCV non-nucleoside polymerase inhibitor discovery program and has advanced ... of hepatitis C." IDX184 Nucleotide Prodrug polymerase Inhibitor IDX184 is a once-daily, oral ...Pharmasset Receives Notice of Allowance
... a prodrug of PSI-6130, a nucleoside analogue polymerase inhibitor of HCV, is being developed ... PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that Pharmasset has nominated as ... in our growing pipeline of HCV nucleoside polymerase inhibitors," stated Schaefer Price, Pharmasset's ...Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
... including promising second-generation polymerase and protease inhibitor compounds for the ... San Francisco, CA. Second-Generation Nucleoside polymerase Inhibitor Program Idenix's preclinical HCV nucleoside polymerase inhibitor program comprises two novel nucleotide ...Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
... of clevudine was examined using an endogenous HBV polymerase assay. The mode of inhibition for clevudine ... be binding at or near the active site of the HBV polymerase without being utilized as a substrate. To the ... prodrug of PSI-6130, a cytidine nucleoside analog polymerase inhibitor, for treatment of HCV. A 14-day ...... support the potential for IDX184 to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and tolerability, coupled ... new drug applications in the coming months from our non-nucleoside polymerase inhibitor and protease inhibitor programs, we are closer to achieving our ...
TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
... allows precise control at the start of PCR thermal cycling by blocking DNA polymerase nucleotide incorporation until heat activated. The temperature dependent control of DNA polymerase extension vastly reduces mis-priming, primer dimer formation and other ...... first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic ... study to further support the efficacy and safety of R7128, and nucleoside polymerase inhibitors as a class," said Michelle Berrey, MD, MPH, Pharmasset's Chief ...
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
... in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Investigational ... than the active metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence ...Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
... drugs in the anti-infective field. Enanta is developing novel protease, polymerase and cyclophilin-based inhibitors targeted against the Hepatitis C virus ... in various states of development include protease inhibitors (ABT-450) and polymerase inhibitors (ABT-333 and ABT-072). In addition to developing HCV ...Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
... Company Developing Non-Nucleoside polymerase Inhibitor for Treatment of Hepatitis C SAN ... C and oncology. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an oral ...... hepatitis C virus (HCV). PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice ... to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through its collaboration ...
... Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar ... 1 Study of BSI-201, a Small Molecule Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with Advanced Solid Tumors When: Monday, ...
... infectious diseases, today announced preclinical data from the company's polymerase and protease inhibitor programs for the treatment of hepatitis C. These ... being held this week in Milan, Italy. Second-Generation Nucleoside polymerase Inhibitor Program IDX184 is a nucleotide prodrug derived from Idenix's ...
... in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be ... developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist ...
... preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight ... platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BiPar has successfully advanced BSI-201 from an IND to ...
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
... 14, 2008. The abstract, "Activity of BSI-201, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, alone and in combination with topotecan in human ovarian ... platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead PARP inhibitor program in Phase 2 ...... to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's ... also suggests that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care that is not found with other classes ...
... R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's ... Clinical Development & Chief Medical Officer. "Currently, there are no HCV polymerase inhibitors approved for the treatment of chronic HCV infection. We ...
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
... the most potent antiviral activity of any investigational nucleoside HCV polymerase inhibitor to date in doses suitable for progression into future ... to include direct-acting antiviral drug combinations, and nucleoside polymerase inhibitors such as R7128. For a discussion of these risks and ...... licensed by SEQUENOM and known as the AttoSense(TM) HPV assay). Utilizing SEQUENOM's proprietary MassARRAY((R)) system that couples standard polymerase chain reaction (PCR) techniques with mass spectrometry (PCR-MS), study samples were simultaneously screened, genotyped and quantified for each of 13 ...
Alfacell Provides Shareholder Update
... we added Onconase to three mesothelioma cell lines at a dose which is achievable in humans, and then using molecular biology techniques including polymerase chain reaction, measured the levels of the MDR and nfkB genes after treatment with the drug. Striking decreases in all of these genes in the ...... infection of which certain types can lead to cervical cancer. Great Basin Scientific's technology has several advantages over the traditional polymerase Chain Reaction (PCR) method that requires the skills of highly-trained technicians and often times multiple rooms to avoid cross contamination of ...
... SNY ) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer ....
... and services, today announced that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction (PCR) test to aid in identifying Influenza A H1N1 Swine-origin (H1N1) flu virus ("S-OIV" or "novel H1N1"), also known as the Swine ....
... the Abbott m 2000 Instrument System The Abbott RealTi m e HIV-1 test runs on the Abbott m 2000, an automated system that uses real-time polymerase chain reaction (PCR) to amplify, detect and measure minute levels of virus in blood samples as well as extremely high levels of these infectious ...
... noted that a Phase 2b triple combination trial of ITMN-191 is planned for initiation in the summer of 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "The Phase 1b ...
... blood pressure, or severity of illness requiring supportive care. Of the 137 patients randomized, 122 age 19 to 101 years had influenza confirmed by polymerase chain reaction (PCR) testing and were included in the intent-to-treat infected (ITTI) patient population; 41 patients received oseltamivir 75 mg ...
... for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, ...
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
... "In addition, we are pleased to report that the first dosage cohort has been enrolled in the INFORM-1 study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ever study to investigate the combined effects of two direct antiviral agents in the ...Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
... C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer. Safe Harbor Statement ...Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
... HCV patients. -- Nominated PSI-7851 as a lead product candidate for the treatment of HCV. PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice (GLP) toxicology studies. -- Announced receipt of a Notice of ...... in 31 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in collaboration with Roche. As previously reported for Cohorts 1 and 2 of this study, R7128 ...
First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
... received its Clinical Laboratory Improvement Amendment (CLIA) certificate* for its proprietary licensed testing process, Target Enriched Multiplex polymerase Chain Reaction (Tem-PCR). This molecular differential diagnostic technology is the first Tem- PCR test introduced to the clinical market which is ...... clevudine in South Korea under the brand name Levovir. "Clevudine's unique mechanism of action as a non-chain terminating nucleoside analog HBV polymerase inhibitor may demonstrate additive antiviral benefit in combination with tenofovir's recently demonstrated antiviral potency in HBV," stated Dr. ...
Other Contentsketonesfailurefailurefailurefailurefailurefailurefailurefailurefailurearthroscopyarthroscopykneekneekneekneekneelabialabiakneeskneesknees
Breaking Biology News(10 mins):New management methods extend blackberry season 2Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells 49774 1Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells 49774 2Need something 3F Talk to my right ear 21 49772 1Need something 3F Talk to my right ear 21 49772 2Ontario women live longer but dont prosper 3A Study 49770 1Ontario women live longer but dont prosper 3A Study 49770 2Ontario women live longer but dont prosper 3A Study 49770 3Ontario women live longer but dont prosper 3A Study 49770 4
Breaking Medicine News(10 mins):Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 2Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 3Health News:Physician advice a key motivator in baby's sleep position 2Health News:Physician advice a key motivator in baby's sleep position 3Health News:Casual Sex Doesn't Cause Emotional Damage: Study 2Health News:When Will FDA Speak Out on Toxic Plastics Chemical BPA? 2
Other TagsMerciMerci[0] Better Vaccine Planning Needed, Committee Finds[0] 'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities[0] Physician advice a key motivator in baby's sleep position[0] Casual Sex Doesn't Cause Emotional Damage: Study[0] When Will FDA Speak Out on Toxic Plastics Chemical BPA?
InspirexEvolisMerciPulsavacPowerPulseHERMESEcopulseSurgiGraphicOsteomedKirschenbaumCherfFrommCapelloStulberg
Other Tagsranks 2ranks 3ranks 4deemed 2deemed 3deemed 4deemed 5directed 2directed 3directed 4directed 5directed 6directed 7directed 8directed 9directed 10exploitation 2wisdom 2contrary 2temporarily 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |